Relationship between Systolic Ejection Time and Inflammation in End-Stage Heart Failure

被引:0
作者
Gutovitz, Joel [1 ]
Kutcher, Jonathan [1 ]
Cherney, David Z. [2 ]
Schiller, Yael [1 ]
Gabizon, Itzhak [3 ]
Keshet, Eran [4 ]
Rimon, Jordan [4 ]
Koren, David [5 ]
Rao, Vivek [6 ]
Grosman-Rimon, Liza [7 ]
机构
[1] Technion, Ruth & Bruce Rappaport Fac Med, Haifa, Israel
[2] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON, Canada
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Med Ctr, Dept Cardiol, Beer Sheva, Israel
[4] York Univ, Fac Hlth, Toronto, ON, Canada
[5] Sheba Med Ctr, Dept Cardiac Surg, Tel Hashomer, Israel
[6] Univ Hlth Network, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada
[7] Acad Coll Levinsky Wingate, Wingate Inst, IL-6937808 Netanya, Israel
关键词
end-stage heart failure; inflammation; systolic ejection time; CARDIAC MYOSIN ACTIVATOR; CHEMOKINES; RECEPTORS;
D O I
10.14423/SMJ.0000000000001801
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectivesSystolic ejection time (SET) and systemic inflammation are two essential indicators of heart failure (HF) progression. We aimed to evaluate the associations between SET and inflammatory mediators in end-stage HF. MethodsParticipants included 16 patients with end-stage HF recruited from the Heart Failure Clinic at Toronto General Hospital and 16 healthy individuals free of any known cardiovascular disease. SET, end systolic pressure, and levels of inflammatory mediators were documented for each patient, and a Spearman rank correlation coefficient was performed to examine differences between patients with end-stage HF and healthy controls. ResultsThe mean SET in patients with HF was shorter than in the healthy controls (283.5 +/- 34.3 ms vs 330.1 +/- 19.0 ms, P < 0.001). C-reactive protein (P = 0.001), macrophage inflammatory protein-1 beta (P = 0.041), macrophage-derived chemokine (P = 0.007), and cyclic guanosine monophosphate (P < 0.001) levels were negatively correlated with SET. The levels of other inflammatory mediators-granulocyte-stimulating factor, granulocyte-macrophage colony-stimulating factor, interleukin-8, macrophage inflammatory protein-1, macrophage inflammatory protein-1 alpha, and tumor necrosis factor alpha-were not significantly correlated with SET. ConclusionsWe found that SET was significantly lower in patients with end-stage HF compared with healthy controls and that reduced SET correlated with increased levels of several inflammatory mediators in patients with HF. By better understanding the relationship between SET and inflammation in HF, a more thorough evaluation could lead to improved risk stratification among patients with HF. Future work should investigate the roles of SET and inflammation in HF.
引用
收藏
页码:167 / 170
页数:4
相关论文
共 50 条
  • [1] Association between systolic ejection time and outcomes in heart failure by ejection fraction
    Patel, Priyesh A.
    Ambrosy, Andrew P.
    Phelan, Matthew
    Alenezi, Fawaz
    Chiswell, Karen
    Van Dyke, Melissa K.
    Tomfohr, Jennifer
    Honarpour, Narimon
    Velazquez, Eric J.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (07) : 1174 - 1182
  • [2] Surgical therapy of end-stage heart failure
    Christiansen, S
    Brose, S
    Autschbach, R
    HERZ, 2003, 28 (05) : 380 - 392
  • [3] Advanced Therapies For End-Stage Heart Failure
    Katz, Jason N.
    Waters, Sarah B.
    Hollis, Ian B.
    Chang, Patricia P.
    CURRENT CARDIOLOGY REVIEWS, 2015, 11 (01) : 63 - 72
  • [4] Surgical approach to end-stage heart failure
    Klotz, Stefan
    Scheld, Hans H.
    CURRENT OPINION IN ANESTHESIOLOGY, 2011, 24 (01) : 86 - 91
  • [5] Obesity in patients with end-stage heart failure
    Krol, Bogumila
    Oprzedkiewicz, Aleksandra
    Szczurek, Wioletta
    Szygula-Jurkiewicz, Bozena
    KARDIOCHIRURGIA I TORAKOCHIRURGIA POLSKA, 2018, 15 (03): : 176 - 179
  • [6] Medical treatment of end-stage heart failure
    Binetti, G
    Senni, M
    Colombo, F
    Tasca, G
    Mamprin, F
    Caporale, R
    Ferrazzi, P
    Gamba, A
    Glauber, M
    Troise, G
    Fiocchi, R
    CARDIOVASCULAR DRUGS AND THERAPY, 1996, 10 : 617 - 622
  • [7] Molecular Signatures of End-Stage Heart Failure
    Lin, David
    Hollander, Zsuzsanna
    Meredith, Anna
    Stadnick, Ellamae
    Sasaki, Mayu
    Freue, Gabriela Cohen
    Qasimi, Pooran
    Mui, Alice
    Ng, Raymond T.
    Balshaw, Robert
    Wilson-McManus, Janet E.
    Wishart, David
    Hau, David
    Keown, Paul A.
    McMaster, Robert
    McManus, Bruce M.
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (10) : 867 - 874
  • [8] Inflammation in end-stage renal failure: could it be treated?
    Stenvinkel, P
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 : 33 - 38
  • [9] Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist
    Severino, Paolo
    Mather, Paul J.
    Pucci, Mariateresa
    D'Amato, Andrea
    Mariani, Marco Valerio
    Infusino, Fabio
    Birtolo, Lucia Ilaria
    Maestrini, Viviana
    Mancone, Massimo
    Fedele, Francesco
    DIAGNOSTICS, 2019, 9 (04)
  • [10] Assisted circulation for end-stage chronic heart failure
    Liotta, D
    ARTIFICIAL ORGANS, 1998, 22 (03) : 230 - 236